Acceptability Study on Nutricomp® Drink Plus Fibre in Adults (Fuchsia)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leigh On Sea, United Kingdom, SS9 3AA
- AC Health & Nutrition Ltd
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male and female participants ≥ 18 years of age
- Assessed to have malnutrition or be at risk of malnutrition by a Dietician within the investigator team. Assessment to include, but not limited to weight loss history, current BMI/MUST score, anamnesis, dietary intake history and predicted future oral intake.
- Anticipated period of nutritional support ≥ 12 days
- Patient has the capacity and is willing to provide informed consent.
Exclusion criteria:
- Participants with mental in capabilities who are unable to give informed consent
- Hypersensitivity to any of the active substances or excipients within the IP
- Severely impaired gastrointestinal function or complete failure
- More than 50% of nutrition from Parenteral Nutrition
- Simultaneous participation in another interventional study
- Participants who are unwilling or mentally and/or physically unable to adhere to study procedures
- Participants with dysphagia requiring thickened fluids
- Participants with significant renal impairment (CKD)
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Nutricomp Drink Plus Fibre
Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of gastrointestinal tolerance parameters
Time Frame: Day 1 - day 13
|
Day 1 - day 13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of (further) adverse events during the treatment period (yes/no, if yes timing/duration/assumed cause/seriousness/severity)
Time Frame: Day 1 - day 13
|
Day 1 - day 13
|
|
Palatability evaluation performed under controlled condition using a questionnaire with a 5 point hedonic scale rang
Time Frame: Day 1 - day 13
|
Day 1 - day 13
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HC-G-H-1610
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Patients in Need of High-energy Oral Nutritional Supplementation
-
NCT01070199CompletedHigh and Increasing Contribution of Energy From Beverages in the Diet May Enhance Positive Energy Balance and Weight Gain
-
NCT05905068CompletedTo Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other Comorbidities
-
NCT02066662CompletedAtrial Fibrillation or Pulmonary Embolism | Need of Long Term Oral Anticoagulation Therapy (OAT) | Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
-
NCT05463796RecruitingLung Cancer | Cirrhosis | Barrett Esophagus | Hematologic Malignancy | Non-Alcoholic Fatty Liver Disease | Cancer Risk | Vulvar Intraepithelial Neoplasia | Childhood Cancer Survivors | Lung; Node | Non Alcoholic Steatohepatitis
Clinical Trials on Nutricomp Drink Plus Fibre
-
NCT02538250CompletedOral Nutritional Supplementation
-
NCT04113200Completed
-
NCT06645171Not yet recruiting
-
NCT01534364Completed
-
NCT04400669RecruitingPatient Preference | Patient Safety
-
NCT02078635WithdrawnCardiovascular Diseases | Obesity | Diabetes | Metabolic Syndrome | Hypercholesterolemia
-
NCT02281253CompletedOverweight | Dyslipidemias | Metabolic X Syndrome
-
NCT02949115UnknownObesity | Overweight | Menopause | Aging
-
NCT07141888RecruitingHyperuricemia With or Without Gout